Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of flumatinib in chronic
phase of chronic myeloid leukemia (CML-CP) patients With Ph+ post imatinib failure.
Phase:
Phase 4
Details
Lead Sponsor:
Shenzhen Second People's Hospital
Collaborators:
Dongguan People's Hospital First Affiliated Hospital of Shantou University Medical Collegeity Hainan General Hospital Peking University Shenzhen Hospital Sanya Central Hospital